National Bank of Canada’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$122K Sell
30
-3,000
-99% -$172K ﹤0.01% 1800
2026
Q1
$18.3M Buy
3,030
+145
+5% +$8.45K 0.02% 513
2025
Q4
$15.5M Buy
+2,885
New +$139K 0.01% 589
2025
Q2
Sell
-6,500
Closed -$39.6M 3018
2025
Q1
$39.6M Buy
+6,500
New +$379K 0.04% 355
2022
Q3
Sell
-8,985
Closed -$69.2M 2701
2022
Q2
$69.2M Sell
8,985
-3,011
-25% -$229K 0.32% 77
2022
Q1
$87.6M Buy
+11,996
New +$805K 0.26% 82

Other funds holding BMY

National Bank of Canada's BMY Position: Q2 2026 in Review

National Bank of Canada increased its Bristol-Myers Squibb (BMY) stake by 9.3% in Q2 2026, buying an estimated $12.6M and bringing the position to 2,580,079 shares worth $149M. The position accounts for 0.11% of the portfolio, ranked #162.

National Bank of Canada first reported a position in BMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $166M in Q4 2025. 1,973 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • National Bank of Canada held 2,580,079 shares of Bristol-Myers Squibb worth $149M as of Q2 2026.
  • National Bank of Canada bought 219,777 Bristol-Myers Squibb shares in Q2 2026, an estimated $12.6M.
  • Bristol-Myers Squibb made up 0.11% of National Bank of Canada's portfolio in Q2 2026, its #162 holding.
  • National Bank of Canada first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 19 quarters since.
  • National Bank of Canada's Bristol-Myers Squibb position peaked at $166M in Q4 2025.
  • 1,973 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.